Primary hepatocellular carcinoma (HCC) is a significant tumor worldwide and represents the most common primary hepatic neoplasm. Staging criteria are important for appreciation of timely work up of these neoplasms in contradiction with surgical colleagues. This article demonstrates the appearance of HCC on multiphasic, multidetector CT (MDCT) and relates these findings to current staging criteria. The variable appearance on different planes of contrast is critical to appreciate in staging this neoplasm. The hypervascular nature of the primary tumor makes MDCT and threephase imaging a critical feature in the detection and characterization of this tumor. This is especially critical in the patients who are candidates for surgical resection. Additionally, MDCT has allowed arterial phase imaging to define the vascular supply of the tumor. An accurate representation of the size and number of lesions is critical in not only the initial staging but also the follow-up of hepatocellular carcinoma. The post-treatment features including the appearance post-surgically and after radiofrequency ablation can be well appreciated on MDCT.
Introduction
Hepatocellular carcinoma (HCC) is the eighth most common malignancy worldwide and the most common malignant neoplasm of the liver. Epidemiologically, HCC is most common in Asia and sub-Saharan Africa [1, 2] . The most common risk factors identified include cirrhosis and hepatitis B and C. Additional risk factors include: hemochromatosis, α 1 -antitripsin deficiency, exposure to aflatoxins, Thorotrast administration, oral contraceptives, and vinyl chloride exposure [1, 3] . Hepatitis B is considered the primary cause of approximately 80% of cases worldwide. The peak age group for development is in the 6th to 8th decades with a definite male predominance of 4:1. The median survival rate remains dismal being less than 1 year and a 5-year survival rate of only 2%-5%. [4] There has been some improvement in 1-year survival over the past 5 years, thought to be a reflection of earlier detection of smaller resectable tumors and more aggressive surgical approaches.
Clinical presentation
The most common symptomatology includes: abdominal pain, malaise, fatigue, and weight loss [5] . Findings on physical examination often include an enlarged, irregular, and nodular liver as a result of cirrhotic change. Jaundice and abnormal liver function tests may only be evident later in the course because of the significant functional reserve of the liver parenchyma. Paraneoplastic syndromes are not uncommon including hypercalcemia and hyperglycemia as well as polycythemia which occurs in less than 10% of patients [6] .
Pathology
HCC is the result of a series of events that cause the development of frank malignancy from smaller This paper is available online at http://www.cancerimaging.org. In the event of a change in the URL address, please use the DOI provided to locate the paper.
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lesions. A number of stages have been identified including: cirrhosis and regenerative nodules, dysplastic nodules, early HCC, and advanced HCC [7, 8] . The earliest phase i.e., regenerative nodules are areas of hepatocyte proliferation surrounded by fibrous septa that develop as a non-specific response to liver injury. In contrast to regenerative nodules, the dysplastic nodule is premalignant and represents proliferation of hepatocytes with nuclear variation that can be identified as low-grade to high-grade dysplasia. Early HCC is those lesions that are less than 2 cm in diameter with well-differentiated cells and a preserved trabecular appearance [8] . These early tumors usually have a well-defined margin with a thin fibrous capsule but may demonstrate extra-nodular growth into surrounding liver sinusoids. Large HCCs, those greater than 2 cm, are classified as advanced HCC. These may be nodular, massive, and diffuse. Diffuse HCC results in tumor nodules dispersed within the liver parenchyma. I  T1 N0 M0  II  T2 N0 M0  IIIA  T3 N0 M0  IIIB  T1 N1 M0  T2 N1 M0  T3 N1 M0  IVA  T4 
Staging
Staging of HCC is critical to clinical management and is assessed through the TNM system. The primary lesion is defined by tumor size, number, and location of lesions, invasion of local vascular structures, and extension into the biliary system. Additionally, the staging system evaluates the location of regional, nodal disease and the presence or absence of distant metastases (Table 1 ) [5, [9] [10] [11] . T1 lesions are those that are solitary tumors without vascular invasion, T2 lesions are solitary tumors with vascular invasion or multiple tumors, none larger than 5 cm; T3 represents multiple tumors larger than 5 cm, tumor invading major portal or hepatic venous structures, and T4 lesions are tumors with direct invasion of adjacent organs. Using a binary method, lymph node staging consists of N0 without regional metastases and N1 with regional lymph node metastasis. Distant metastases are defined with M0 being no distant metastasis and M1 being the presence of distant metastasis.
Imaging findings
Computed tomography (CT) and magnetic resonance (MR) are the primary modalities used to obtain imaging studies for the diagnosis and staging of HCC [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] .
In this manuscript we specifically address the use of multidetector CT (MDCT) in the assessment of hepatocellular carcinoma [5, 10] . Although MR imaging may be more sensitive in detecting small lesions, MDCT is highly effective in the detection and staging of HCC. This is, however, significantly dependent upon technique, which must be meticulous with new MDCT scanners. There are three CT-defined phases of contrast enhancement that should be exploited for the accurate detection and staging of HCC. The first phase, the hepatic arterial phase (HAP) occurs at 20-30 s following the administration of contrast material. Contrast material should be given with a bolus injection and power injector and rates should be fast in the range of 4-6 ml/s. Scanning in the second phase should ideally be performed as an early parenchymal phase in the range of 40-55 s, and the third phase, now termed the hepatic venous phase (HVP), previously termed the portal venous phase (PVP) on single detector CT occurs from 65 to 80 s following contrast administration (Fig. 1) . Hypervascular lesions are best imaged during the early arterial phase when they appear as areas of increased enhancement relative to the unenhanced liver parenchyma [5, 11, 12] . Although hypervascular lesions are usually best seen during this phase, they are often also seen during the early parenchymal phase and are usually less well seen during the standard HVP/PVP phases. MDCT also allows for high-quality, thin-section imaging. Scans are ideally performed at less than 1 cm, specifically 5 mm sections. The early phase images can be used to develop a three-dimensional (3D) vascular map. When a capsule is present, it is usually hypodense on the HAP or mixed density on the PVP and showing some enhancement on delayed images. The use of MDCT has essentially replaced CT arterial portography and allows a non-invasive approach to imaging HCC. Multiphasic imaging allows the detection of tumor thrombus within vascular structures most efficiently on the later phase images. One may be able to distinguish between bland tumor thrombus and tumor thrombus by identifying the enhancement of clot in earlier phases. The sensitivity and specificity of MDCT are still evolving with changes in the equipment. This should erode the previously documented limitations of detection although in the background of the cirrhosis, there still are significant limitations in detection. The following images demonstrate the appearance of HCC on MDCT for the various stages using the TNM system as referenced in Table 1 (Figs 2-8 ). The variables of detectability of HCC depend on the phase of contrast administration and each individual tumor is important to appreciate (Figs 9-11 ).
Treatment options
The treatment of HCC includes surgery, chemotherapy, radiation therapy, and, most importantly, combination therapies. Data from the National Cancer Data Bank (NCDB) reported that approximately 17.7% of patients were treated with chemotherapy alone, 17% with surgery alone, and 3.2% with radiation therapy [25] [26] [27] [28] [29] .
Surgery
Surgery is considered the primary treatment option for candidates in stages 1, 2, or 3a. In these cases, surgical removal can be performed by either immediate tumor resection or by orthotopic liver transplantation. The 5-year survival rates for these patients following liver transplantation ranges from 58% to 75% [3] [4] [5] [6] [7] [24] [25] [26] . For resection, 5-year survival ranges from 35% to 51% [25] . The recurrence rate after resection has been reported to be as high as 1/3 of patients with a recurrence rate of 3%-17% for orthotopic liver transplantation [30] . The 5-year survival rates for single lesions smaller than 5 cm has been reported as 63% [31] . Larger tumors, however, are associated with poorer outcomes especially in the absence of a tumor capsule, the presence of multiple nodules, satellite lesions, or the presence of vascular invasion. 
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Other treatment options
Percutaneous therapies such as ethanol injection, transarterial catheter embolization, cryoablation, and radiofrequency ablation (RFA), are secondary treatment options. RFA is a common therapeutic option for tumors smaller than 3 cm and results in 5-year survival rates of just less than 50% [32] (Fig. 12) . Adjuvent systemic chemotherapy has been used with single and multiple agents including 5-fluoro uracil, interferon, cisplatinum, thalidomide, octreotide, and tamoxifen.
